Business Context and Reporting Period
Pulsenmore Ltd. filed Form 6-K on January 26, 2026, reporting a significant commercial development with Clalit Health Services, Israel's largest HMO. The filing details the execution of a new agreement following the successful completion of a feasibility trial for the Pulsenmore FC, a device for at-home follicular monitoring for IVF and fertility preservation.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Terms
On January 21, 2026, Pulsenmore and Clalit entered into the "2026 Agreement," modifying the terms of their 2021 Agreement. Key changes include:
- Pilot Period: An 18-month pilot period was established where Pulsenmore sells and markets the device directly to Clalit patients, supported by Beilinson NEXT (Rabin Medical Center's virtual hospital platform).
- Extended Term: Upon pilot completion, the engagement extends for a five-year term, increased from the original four-year term.
- Purchase Commitment: Clalit committed to a minimum annual purchase of 2,000 Pulsenmore FC units. Units sold directly by Pulsenmore to Clalit patients will be deducted from this minimum.
- Return Rights: Clalit retains the right to return up to 1,000 units per year and the right to sell units directly to patients during both the pilot and the five-year term.
Outlook, Risks, and Management Commentary
Management confirmed that the feasibility trial conducted at Rabin Medical Center met all protocol criteria, triggering the new agreement. On January 26, 2026, the Company issued a press release announcing the launch of the first at-home follicular monitoring service for IVF and fertility preservation in partnership with Clalit. The filing notes that the description of the agreement is subject to the full text, which will be included as an exhibit to the Annual Report on Form 20-F for the year ended 2025.
Investor Verification Checklist
- Verify the full text of the 2026 Agreement in the upcoming Form 20-F for the year ended 2025.
- Confirm the specific commercial terms regarding the deduction of direct sales from Clalit's minimum purchase commitment.
- Monitor the progress of the 18-month pilot period and the transition to the five-year term.
- Review the attached press release (Exhibit 99.1) for additional details on the service launch.